Government ❯Regulation ❯FDA

Drug Approval

Compounding Pharmacies Mifepristone Patient Safety Psychedelic Drug NDA New Drug Application Mifepristone Approval Public Health Safety

FDA Investigates Fatal Liver Failures Linked to Sarepta’s Elevidys Therapy

Two teenage deaths within 90 days of infusion prompted Sarepta to suspend shipments to non-ambulatory patients.

Democratic-Led States Petition FDA to Remove Mifepristone Restrictions

Texas Judge Allows Republican-Led States to Challenge Abortion Pill Regulations

Illegal Online Pharmacies Selling Dangerous Weight Loss Drugs

FDA Encourages Lower Doses in Cancer Drug Testing

FDA Reviews MDMA-Assisted Therapy for PTSD as Congress Pushes Psychedelic Research